Amgen’s injectable drug for Rheumatoid Arthritis, Enbrel, was patented in 1998, and the patent has just been extended to 2029 (for reasons IDK). Subject to vigorous appeals in US courts.
Enbrel earned Amgen $1.3 Billion in Q2 alone this year. Average cost - over US$2700 PER MONTH.
Then think about the OA market compared to the RA market......
research reports and media, page-55
-
- There are more pages in this discussion • 4,114 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.020(8.33%) |
Mkt cap ! $90.94M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 26.0¢ | 24.5¢ | $195.9K | 781.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38000 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 102892 | 9 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |